Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 2;21(17):6388.
doi: 10.3390/ijms21176388.

Human Cell Modeling for Cardiovascular Diseases

Affiliations
Review

Human Cell Modeling for Cardiovascular Diseases

Melania Lippi et al. Int J Mol Sci. .

Abstract

The availability of appropriate and reliable in vitro cell models recapitulating human cardiovascular diseases has been the aim of numerous researchers, in order to retrace pathologic phenotypes, elucidate molecular mechanisms, and discover therapies using simple and reproducible techniques. In the past years, several human cell types have been utilized for these goals, including heterologous systems, cardiovascular and non-cardiovascular primary cells, and embryonic stem cells. The introduction of induced pluripotent stem cells and their differentiation potential brought new prospects for large-scale cardiovascular experiments, bypassing ethical concerns of embryonic stem cells and providing an advanced tool for disease modeling, diagnosis, and therapy. Each model has its advantages and disadvantages in terms of accessibility, maintenance, throughput, physiological relevance, recapitulation of the disease. A higher level of complexity in diseases modeling has been achieved with multicellular co-cultures. Furthermore, the important progresses reached by bioengineering during the last years, together with the opportunities given by pluripotent stem cells, have allowed the generation of increasingly advanced in vitro three-dimensional tissue-like constructs mimicking in vivo physiology. This review provides an overview of the main cell models used in cardiovascular research, highlighting the pros and cons of each, and describing examples of practical applications in disease modeling.

Keywords: cardiovascular disease; co-cultures; disease modeling; embryonic stem cells; engineered 3D tissue; heterologous system; human cell model; human induced pluripotent stem cell; primary cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Disease Modeling Complexity. A schematic overview of the increasing complexity of the main cell models commonly used for cardiovascular diseases (CVDs) and their relative availability for increasingly complex methodologies.

Similar articles

Cited by

References

    1. Benjamin E.J., Muntner P., Alonso A., Bittencourt M.S., Callaway C.W., Carson A.P., Chamberlain A.M., Chang A.R., Cheng S., Das S.R., et al. Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association. [(accessed on 26 June 2020)]; Available online: https://pubmed.ncbi.nlm.nih.gov/30700139/ - PubMed
    1. Jimenez-Tellez N., Greenway S.C. Cellular models for human cardiomyopathy: What is the best option? World J. Cardiol. 2019;11:221–235. doi: 10.4330/wjc.v11.i10.221. - DOI - PMC - PubMed
    1. Garbern J.C., Mummery C.L., Lee R.T. Model Systems for Cardiovascular Regenerative Biology. Cold Spring Harb. Perspect. Med. 2013;3 doi: 10.1101/cshperspect.a014019. - DOI - PMC - PubMed
    1. Sommariva E., Stadiotti I., Perrucci G.L., Tondo C., Pompilio G. Cell models of arrhythmogenic cardiomyopathy: Advances and opportunities. Dis. Model. Mech. 2017;10:823–835. doi: 10.1242/dmm.029363. - DOI - PMC - PubMed
    1. Hu J., Han J., Li H., Zhang X., lan Liu L., Chen F., Zeng B. Human Embryonic Kidney 293 Cells: A Vehicle for Biopharmaceutical Manufacturing, Structural Biology, and Electrophysiology. Cells Tissues Organs. 2018;205:1–8. doi: 10.1159/000485501. - DOI - PubMed